Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector Price Performance
Shares of NASDAQ:ALEC opened at $13.06 on Monday. The company's 50 day simple moving average is $10.19 and its 200 day simple moving average is $12.10. Alector has a fifty-two week low of $7.50 and a fifty-two week high of $29.30. The firm has a market capitalization of $1.09 billion, a P/E ratio of 33.49 and a beta of 1.08.
Alector (NASDAQ:ALEC - Get Rating) last announced its earnings results on Thursday, August 4th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.47) by $0.59. Alector had a net margin of 12.06% and a return on equity of 12.16%. Sell-side analysts expect that Alector will post -1.36 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. Mizuho assumed coverage on Alector in a research note on Wednesday, July 6th. They issued a "buy" rating and a $15.00 price target on the stock. Citigroup reduced their price target on shares of Alector from $34.00 to $19.00 and set a "buy" rating for the company in a research report on Monday, July 11th. Barclays cut their price objective on Alector from $42.00 to $14.00 in a research report on Wednesday, May 11th. Finally, The Goldman Sachs Group lowered their price objective on shares of Alector from $9.00 to $6.00 and set a "sell" rating for the company in a research note on Tuesday, May 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Alector has an average rating of "Moderate Buy" and a consensus price target of $20.86.